First fully integrated spatial multiomic assay from 10x Genomics (TXG) brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...

On 4, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in UK government ...

PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region ASTRA will bring together molecular and spatial data ...

After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput "Seeing the Xenium Prime 5K data reminded me of the ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. 10x Genomics is collaborating with PharosAI and leading UK institutions to build ...